APA (7th ed.) Citation

Chen, X., Wang, F., Cheng, Y., Cao, M., Mei, K., Chu, X., . . . Gong, X. (2026). Surufatinib plus anti‐PD‐1/PD‐L1 antibody as second‐line therapy for advanced biliary tract cancer: A single‐centre investigator‐initiated trial. Clinical & Translational Discovery, 6(1), 1. https://doi.org/10.1002/ctd2.70123

Chicago Style (17th ed.) Citation

Chen, Xinni, Feng Wang, Yuan Cheng, Mengran Cao, Kuimin Mei, Xiaoyuan Chu, Fang Dai, and Xinlei Gong. "Surufatinib Plus Anti‐PD‐1/PD‐L1 Antibody as Second‐line Therapy for Advanced Biliary Tract Cancer: A Single‐centre Investigator‐initiated Trial." Clinical & Translational Discovery 6, no. 1 (2026): 1. https://doi.org/10.1002/ctd2.70123.

MLA (9th ed.) Citation

Chen, Xinni, et al. "Surufatinib Plus Anti‐PD‐1/PD‐L1 Antibody as Second‐line Therapy for Advanced Biliary Tract Cancer: A Single‐centre Investigator‐initiated Trial." Clinical & Translational Discovery, vol. 6, no. 1, 2026, p. 1, https://doi.org/10.1002/ctd2.70123.